MAP2K1 and colorectal carcinoma: The model successfully predicted the combination of atezolizumab (anti-PD-L1) and cobimetinib (MEK1/2 inhibitor) to not be effective in metastatic colorectal cancer (CRC), consistent with the phase 3 IMblaze370 trial, where the combination failed to improve overall survival compared to regorafenib [17].